FDA approves nivolumab for treatment of patients with advanced oesophageal squamous cell carcinoma after prior fluoropyrimidines and platinum based chemotherapy

Approval is based on phase 3 ATTRACTION-3 trial (n=419) in which nivolumab demonstrated superior overall survival (10.9 vs 8.4months; HR 0.77; 95% CI: 0.62-0.96; p=0.0189) versus taxane chemotherapy (investigator’s choice of docetaxel or paclitaxel).


Biospace Inc.